82586-62-7

Basic information

• Product Name: 1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride
• Synonyms: 6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID HYDROCHORIDE;(S)-(-)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-3-carboxylic acid hydrochloride;Moexipril Related CoMpound E;(S)-(-)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride 97%;Moexipril USP Related Compound E: (S)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;(S)-(-)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride;DL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID HYDROCHLORIDE;1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID HYDROCHLORIDE
• CAS NO: 82586-62-7
• Molecular Formula: C₁₂H₁₅NO₄*ClH
• Molecular Weight: 273.71
• EINECS: 255-610-1
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Carboxylic Acids;Quinolines, Isoquinolines & Quinoxalines;Chiral Building Blocks;Heterocyclic Building Blocks;Isoquinolines;Carboxylic Acids;Quinolines, Isoquinolines & Quinoxalines
• Mol File: 82586-62-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: 434.8 °C at 760 mmHg
• Flash Point: 216.7 °C
• Appearance: off-white crystalline powder
• Vapor Pressure: 2.49E-08mmHg at 25°C
• Storage Temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
• Solubility: Aqueous Acid
• CAS DataBase Reference: 1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride(82586-62-7)
• EPA Substance Registry System: 1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride(82586-62-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 82586-62-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 82586-62-7 differently. You can refer to the following data:
1. Moexipril intermediate
2. Moexipril intermediate.

InChI:InChI=1/C12H15NO4.ClH/c1-16-10-4-7-3-9(12(14)15)13-6-8(7)5-11(10)17-2;/h4-5,9,13H,3,6H2,1-2H3,(H,14,15);1H/t9-;/m0./s1

Upstream product

• 617699-47-5 (S)-1,2,3,4-tetrahydro-6,7-dihydroxy-2-(tert-butyloxycarbonyl)-3-isoquinolinecarboxylic acid 
• 138908-56-2 (S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester 
• 50-00-0 formaldehyd 
• 358627-67-5 (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-(tert-butyloxycarbonyl)-3-isoquinolinecarboxylic acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 109278-11-7 (S)-(+)-methyl 2-benzoylamino-3-(3,4-dimethoxyphenyl)propanoate 
• 76313-29-6 methyl (Z)-2-benzoylamino-3-(3,4-dimethoxyphenyl)-2-propenoate 
• 25349-37-5 (Z)-2-phenyl-4-(3,4-dimethoxybenzylidene)-(4H)-1,3-oxazol-5-one 
• 69274-24-4 (S)-2-amino-3-(3,4-dimethoxyphenyl)propanoic acid hydrochloride 
• 32161-30-1 (S)-3,4-dimethoxyphenylalanine 

Downstream Products

• 103733-66-0 tert-butyl (S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 103733-32-0 (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethylester, hydrochloride 

Relevant articles and documents

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives

The present invention relates to a process for the production of (S)-1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid compounds (1) and their derivatives from Levodopa (L-Dopa). The ultimately prepared compounds are used as intermediates for, but not limited to, the preparation of substituted derivatives of 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid wherein R1is hydrogen, lower alkyl, C2-C12 acyl, or R1O together are methylenedioxy; R2is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl or substituted aralkyl group; and R3is hydrogen, C2-C12 acyl group, benzyl, alkoxylcarbonyl group, or aralkoxyl carbonyl group.

Optically Pure (S)-6,7-dimethoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid and asymmetric hydrogenation studies related to its preparation

-